

Business updates

September 04, 2018 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, has on 31 August 2018 released its Appendix 4E and Preliminary Final Report for the twelve months ended 30 June 2018. In addition to the financial results as disclosed in the Preliminary Final Report, Invitrocue would also like to provide the following highlights of the company for the financial year ended 30 June 2018.

Highlights of the Reporting Period include:

- Screening of first commercial Onco-PDO™ customer for the indication of colorectal cancer
- Incorporation of corporate entities in United Kingdom and Germany in advance of European launch of Onco-PDO™
- Strengthening scientific advisory board, welcoming Prof. Dr. Christian Peschel
- Successfully raised S\$5.9 million to accelerate global roll-out of Onco-PDO™ at a premium market price

The period under review marked one of significant progress for Invitrocue as the company focuses on the global commercial roll-out of its proprietary Onco-PDO™ drug sensitivity test. Following the screening of the first commercial customer in Singapore in April 2018, the pioneering technology has been well received by leading physicians and patients in a number of indications and has been made available to patients in Hong Kong. Onco-PDO™'s important contribution to the development of more personalised treatment strategies is well-understood and welcomed by healthcare professionals who are committed to improving treatment outcomes.

As Invitrocue now prepares to make Onco-PDO™ available to patients in the United Kingdom, a new corporate entity was established in Northern Ireland. In July, the company established a second European corporate entity in Germany and identified facilities in Germany that will serve as the European reference laboratory. In addition to building the company's own commercialisation capabilities, management continues to review potential scientific commercialisation partnerships.

In line with the company's strategy to strengthen its Scientific Advisory Board ("SAB") as the business evolves, the company welcomed Prof. Dr. Christian Peschel to the SAB. Dr Peschel is an internationally renowned researcher in the fields of hematology and tumour biology. He was most recently Head of Oncology at Klinikum Rechts der Isar in Germany and will provide strategic guidance to Invitrocue's clinical team.

During the period, Invitrocue raised a total of S\$5,904,229 in new funds via the placement of shares and warrants. The new funds will be used to finance the international roll-out of Onco-PDO™, making the innovative technology accessible to patients in Europe and Asia Pacific. The private placement was done at a premium to market, demonstrating confidence from investors in the company's pathway to market.

Commenting on the annual results, Dr Steven Fang, Executive Director, Invitrocue, said:

"This has been an important year for Invitrocue and we look ahead with confidence. Following the first commercial screening with Onco-PDO™, we remain focused on increasing utilisation of our technology through a targeted commercialisation strategy. Investors have shown strong support for

the company as evidenced in our recent fundraising at a premium to market price and we are well positioned to realise our growth opportunities.

“We are implementing a far-reaching education campaign on the potential for personalised treatment plans and look forward to hosting our inaugural oncology summit in October, bringing together leading international experts in oncology to discuss ways in which we can transform the treatment of cancer.”

Conference call details

There will be a conference call for investors and analysts on Thursday, 6 September, hosted by Executive Director, Dr Steven Fang. If you wish to submit questions in advance please direct them to Invitrocue@spurwingcomms.com

Thursday, September 6, 2018

16:00 Sydney, +61 (0) 2 8015 2088

14:00 Singapore, +65 3158 7288

08:00 Munich, +49 (0) 30 3080 6188

07:00 London, +44 (0) 20 3051 2874

Access Code: 841 725 221

To join the call from PC, Mac, Linux, iOS or Android [click here](#).

Additional international numbers available [here](#)

- ENDS -

For more information contact:

Martin D. Bach, VP Operations

T: +65 6460 0497

martind.bach@invitrocue.com

About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com